Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose

Chemotherapy

Volumn 57, Issue 2, 2011, Pages 97-107

  Wagenlehner, Florian M E ^a   Wagenlehner, Christine M ^b   Blenk, Birgit ^d   Blenk, Holger ^d   Schubert, Sabine ^e   Dalhoff, Axel ^e   Naber, Kurt G ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Agaplesion Evangelisches Krankenhaus Mittelhessen   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Department of Microbiology ^*  (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Finafloxacin; Pharmacodynamics; Urinary bactericidal titers; Urine pharmacokinetics

Indexed keywords

CIPROFLOXACIN; FINAFLOXACIN; LEVOFLOXACIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ALKALINIZATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACILLUS SUBTILIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BODY MASS; BODY WEIGHT; COLONY FORMING UNIT; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG STRUCTURE; DRUG URINE LEVEL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE; URINALYSIS; URINARY BACTERICIDAL TITER; URINE ACIDIFICATION; URINE PH; URINE VOLUME;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS, URINARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICROBIAL SENSITIVITY TESTS; PLACEBOS; URINE;

EID: 79952055853     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321028     Document Type: Article

References (37)

1. Bedenic B, Topic M, Budimir A, Bubonja M: Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model. Chemotherapy 2006; 52: 293-297. (Pubitemid 44608666)
2. Kahlmeter G: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003; 51: 69-76. (Pubitemid 36163829)
3. Naber KG, Schito G, Botto H, Palou J, Mazzei T: Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-1175.
4. Naber KG, Well M, Hollauer K, Kirchbauer D, Witte W: In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens. Chemotherapy 1998; 44: 77-84. (Pubitemid 28105418)
5. Wagenlehner FM, Niemetz AH, Weidner W, Naber KG: Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994- 2005. Int J Antimicrob Agents 2008; 31(suppl 1):S25-S34.
6. Stamm W: Treatment of acute uncomplicated urinary tract infection; in Bergan T (ed): Urinary Tract Infections. Basel, Karger, 1997, vol 1, pp 1-7.
7. Eliopoulos GM, Eliopoulos CT: Activity in vitro of the quinolones; in Hooper DC, Wolfson JS (eds): Quinolone Antimicrobial Agents. Washington, American Society for Microbiology, 1993, vol 2, pp 161-193.
8. Naber K: Antibacterial activity of antibacterial agents in urine: an overview of applied methods; in Bergan T (ed): Urinary Tract Infections. Basel, Karger, 1997, vol 1, pp 74-83.
9. Kresken M, Körber-Irrgang B, Labischinski H, Stubbings W: Effect of pH on the in vitro activity of finafloxacin against Gram-negative and Gram-positive bacteria (abstract No F1-2037). 48th ICAAC, Washington, 2008.
10. Schubert S, Stubbings W, Dalhoff A: Comparative inhibitory and bactericidal activities of finafloxacin and ciprofloxacin against Gram-negative and Gram-positive UTIpathogens under physiological conditions and at varying pH-values (abstract No F1- 2041). 48th ICAAC, Washington, 2008.
11. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H: Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin- sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother 2010; 54: 1613-1615.
12. Naber KG, Sörgel F: Antibiotic therapy: rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003; 35: 331-335. (Pubitemid 37363528)
13. Patel H, Andresen A, Vente A, Heilmann HD, Stubbings W, Seiberling M, Lopez-Lazaro L, Pokorny R, Labischinski H: Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother, submitted.
14. Wohlert SE, Jaetsch T, Gallenkamp B, Knops HJ, Lui N, Preisse M, Haebich D, Labischinski H: New fluoroquinolone finafloxacin HCl (FIN): route of synthesis, physicochemical characteristics and activity under neutral and acid conditions. 48th ICAAC, Washington, 2008.
15. Naber KG, Theuretzbacher U, Kinzig M, Savov O, Sörgel F: Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1659-1665. (Pubitemid 28311558)
16. Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG: Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006; 28: 551-559. (Pubitemid 44779182)
17. Wagenlehner FM, Wydra S, Onda H, Kinzig- Schippers M, Sörgel F, Naber KG: Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003; 47: 3789-3794. (Pubitemid 37484990)
18. CLSI: Methods for dilution in antimicrobial susceptibility tests for bacteria that grow aerobically: approved guideline, ed 7. Approved Standard M7-A7. Wayne, Clinical and Laboratory Standards Institute, 2006.
19. Griffith DP, Musher DM, Itin C: Urease: the primary cause of infection-induced urinary stones. Invest Urol 1976; 13: 346-350.
20. Edberg S: The measurement of antibiotics in human body fluids: techniques and significance; in Lorian V (ed): Antibiotics in Laboratory Medicine. Baltimore, Williams & Wilkins, 1986, pp 466-467.
21. Naber CK, Hammer M, Kinzig-Schippers M, Sauber C, Sörgel F, Bygate EA, Fairless AJ, Machka K, Naber KG: Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 3524-3530. (Pubitemid 33107872)
22. Shah PM, Ottnad-Walz M, Stille W: In vitro activity of norfloxacin in synthetic media and human urine compared to that of cinnoxacin [sic!], nalidixic acid and pipemidic acid. Methods Find Exp Clin Pharmacol 1983; 5: 731-734. (Pubitemid 14197104)
23. Shah PM, Ottrad M, Stille W: In vitro activity of norfloxacin in urine compared to that of cinnoxacin [sic!], nalidixic acid and pipemidic acid. Eur J Clin Microbiol 1983; 2: 272-274.
24. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86. (Pubitemid 44968990)
25. Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-268. (Pubitemid 34308974)
26. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10, quiz 11-12.
27. Schentag JJ, Gilliland KK, Paladino JA: What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32(suppl 1):S39-S46. (Pubitemid 32506745)
28. Dalhoff A: Pharmacokinetics of selected antibacterial agents; in Schönfeld H (ed): Antibiotics and Chemotherapy. Basel, Karger, 1998, vol 49, pp 85-108.
29. Karabalut N, Drusano GL: Pharmacokinetics of the quinolone antimicrobial agents; in Hooper DC, Wolfson JS (eds): Quinolone Antimicrobial Agents. Washington, American Society for Microbiology, 1993, vol 2, pp 195-223.
30. Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Naber KG: Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2006; 50: 3947-3949. (Pubitemid 44684924)
31. Well M, Naber KG, Kinzig-Schippers M, Sörgel F: Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Agents 1998; 10: 31-38. (Pubitemid 28234358)
32. Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG: Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother 2009; 53: 1567-1573.
33. Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H: Transintestinal elimination of ciprofloxacin. Chemotherapy 1990; 36: 77-84. (Pubitemid 20079269)
34. Cohen P: Effect of ciprofloxacin on growth of E coli in mouse bladder mucus (abstract No. 472). 18th Int Congr Chemother, Stockholm, 1993.
35. Goh CY, Goh F, Stubbings W, Kroll H-P, Labischinski H: Bactericidal activity of finafloxacin against difficult to kill growth forms of Escherichia coli (abstract No. F1- 2042). 48th ICAAC, Washington, 2008.
36. Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, Naber KG: Pharmacokinetics of ciprofloxacin XR (1,000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006; 27: 7-14. (Pubitemid 43042416)
37. Boy D, Well M, Kinzig-Schippers M, Sörgel F, Ankel-Fuchs D, Naber KG: Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004; 23(suppl 1):S6-S16. (Pubitemid 38376044)